ANI PHARMACEUTICALS, INC Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
ANI PHARMACEUTICALS, INC (ANIP) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of -$2.81 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2019-08-07
- ANI PHARMACEUTICALS, INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2019-06-30 was -$2.81M, a 1402.78% decline year-over-year.
- ANI PHARMACEUTICALS, INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2019-03-31 was -$1.82M.
- ANI PHARMACEUTICALS, INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2018-12-31 was -$912.00K.
- ANI PHARMACEUTICALS, INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2018-09-30 was $317.00K.
- ANI PHARMACEUTICALS, INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2018 was -$379.00K.
- ANI PHARMACEUTICALS, INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2017 was $0.00.
- ANI PHARMACEUTICALS, INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2016 was $0.00.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$2.81M 10-Q · filed 2019-08-07 | -$4.63M 10-Q · filed 2019-08-07 | -$5.55M derived: sum of 3 quarters · filed 2019-08-07 | -$5.23M derived: sum of 4 quarters · filed 2019-08-07 |
| 2019-03-31 | -$1.82M 10-Q · filed 2019-05-09 | -$2.73M derived: sum of 2 quarters · filed 2019-05-09 | -$2.42M derived: sum of 3 quarters · filed 2019-05-09 | -$2.20M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-12-31 | -$912.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$595.00K derived: sum of 2 quarters · filed 2019-02-27 | -$379.00K derived: sum of 3 quarters · filed 2019-08-07 | -$379.00K 10-K · filed 2019-02-27 |
| 2018-09-30 | $317.00K 10-Q · filed 2018-11-06 | $533.00K derived: sum of 2 quarters · filed 2019-08-07 | $533.00K 10-Q · filed 2018-11-06 | $533.00K derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-06-30 | $216.00K 10-Q · filed 2019-08-07 | $216.00K 10-Q · filed 2019-08-07 | $216.00K derived: sum of 3 quarters · filed 2019-08-07 | $216.00K derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-05-09 | $0.00 derived: sum of 3 quarters · filed 2019-05-09 | $0.00 derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $0.00 derived: sum of 3 quarters · filed 2019-02-27 | $0.00 10-K · filed 2019-02-27 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |